TG Therapeutics to present initial azer-cel Phase 1 results in primary progressive MS at MSToronto2026
TGTX•TG Therapeutics plans to present initial Phase 1 azer-cel results in primary progressive multiple sclerosis on October 23 at MSToronto2026; the late-breaking abstract is scheduled for release October 21.
1. Presentation schedule
TG Therapeutics said it will present initial results from the Phase 1 TG-Azercel-101 study of azer-cel in primary progressive multiple sclerosis on October 23 at MSToronto2026. The data have not yet been presented, and the full late-breaking abstract is scheduled for release October 21.
2. Other meeting updates
The company's meeting slate also includes BRIUMVI updates on long-term outcomes, real-world use, dosing changes and a subcutaneous program.
